What did the PCAC vote on in July 2026?

The FDA Pharmacy Compounding Advisory Committee (PCAC) met July 23–24, 2026 to vote on whether seven peptide bulk drug substances — BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon — should be recommended for inclusion on the Section 503A Bulk Drug Substances List. The 503A Bulks List governs which substances licensed compounding pharmacies may use to compound preparations for individual patients. FDA staff's pre-meeting recommendation was against adding all seven. The PCAC vote is advisory and non-binding; FDA must complete formal rulemaking before any regulatory change takes effect.

Does the PCAC vote affect Titan's ability to sell BPC-157, TB-500, or Semax?

No. The PCAC review is about the 503A compounding pharmacy framework — whether licensed pharmacies can compound these substances for patients under prescriptions. Titan Peptide Lab is a research-use-only (RUO) supplier, not a 503A compounding pharmacy. The RUO and compounding pharmacy channels operate under different legal frameworks. An unfavorable PCAC recommendation — or even a subsequent FDA rule excluding these compounds from the 503A list — does not affect the legality of Titan supplying BPC-157, TB-500, Semax, or DSIP as RUO research compounds for in-vitro laboratory use.

If PCAC votes against BPC-157, is it now illegal to buy or sell?

No. A negative PCAC recommendation means the committee is advising FDA not to add BPC-157 to the 503A Bulks List for compounding pharmacies. It does not ban the compound, change its status as a research chemical, or make it illegal to purchase as an RUO research compound. BPC-157 is currently not on the 503A Bulks List anyway — compounding pharmacies already cannot legally use it under 503A. The PCAC vote and any subsequent FDA rulemaking would formalize that existing status, not create a new restriction. For researchers purchasing it as an RUO compound for in-vitro laboratory research, the legal basis is different from the compounding framework.

Why did FDA staff recommend against all seven peptides?

FDA staff applied the three-part 503A test: USP monograph (none qualify); FDA-approved drug component (none qualify); clinical need not adequately met by approved drugs. For the clinical need criterion, FDA staff concluded that the evidence base for each nominated indication is insufficient — primarily animal studies with limited, early-phase, or non-replicated human data. For BPC-157, the evidence is overwhelmingly animal-model data with only small human pilots. For Semax, the primary evidence is Russian clinical studies that haven't been replicated in Western trials. For TB-500, human safety data exists for the parent Thymosin β4 (RGN-259 ophthalmic Phase 2/3) but not specifically for the TB-500 fragment.

When will the PCAC vote result be official?

The PCAC committee discussion and vote occurred July 23–24, 2026. The vote transcript and meeting records are published by FDA as part of the public record, typically within weeks to months after the meeting. However, the PCAC vote is advisory — the regulatory outcome depends on FDA's formal rulemaking response, which typically takes 12–24 months or more after the advisory committee meeting. Titan will update the individual compound legal-status pages (BPC-157, TB-500, Semax, DSIP) with confirmed outcomes once the official FDA record is published.

FDA PCAC July 2026 · 7 peptides · 503A Bulks List review

PCAC peptide vote July 2026 — what the FDA advisory committee meeting means for BPC-157, TB-500, Semax, and five others.

On July 23–24, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) met at FDA's White Oak Campus in Silver Spring, Maryland to review seven peptide bulk drug substances for potential inclusion on the Section 503A Bulk Drug Substances List (docket FDA-2025-N-6895). The 503A Bulks List is the regulatory framework that determines which substances licensed compounding pharmacies in the United States may use to prepare customized preparations for individual patients. The seven peptides under review span two days: July 23 covered BPC-157 (body protection compound, for ulcerative colitis indication), KPV (Lys-Pro-Val α-MSH fragment, for wound healing), TB-500 (LKKTETQ Thymosin β4 fragment, for wound healing), and MOTS-c (mitochondria-derived peptide, for obesity and osteoporosis). July 24 covered Emideltide/DSIP (delta sleep-inducing peptide, for insomnia, opioid withdrawal, narcolepsy), Semax (ACTH 4-10 heptapeptide analog, for cerebral ischemia, migraine, trigeminal neuralgia), and Epitalon (AEDG tetrapeptide, for insomnia). FDA staff's pre-meeting briefing (June 29–30) recommended AGAINST adding any of the seven to the 503A list, citing insufficient clinical evidence for the nominated indications. The PCAC vote is advisory — it is a recommendation, not a regulatory decision. FDA must still complete formal rulemaking to add or reject substances from the 503A list. This page explains the regulatory process, the status of each compound, and — critically — what this vote means and doesn't mean for the RUO research supply space. All Titan products are research-use-only compounds, not compounded medications.

BPC-157 research vial — $54.99 (in stock)TB-500 research vial — $89.99 (in stock)

What the PCAC is and what the July meeting covers

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory committee of independent experts (pharmacists, physicians, scientists, consumer representatives) that advises FDA on whether nominated bulk drug substances are appropriate for inclusion on the Section 503A Bulks List. 503A covers traditional compounding pharmacies that compound customized preparations for individual patients under prescriptions from licensed practitioners. A substance added to the 503A Bulks List may be compounded legally by 503A pharmacies; a substance not on the list may not. The PCAC does NOT vote on whether a compound is generally legal, safe, or appropriate for research use — only on whether it belongs in the compounding pharmacy framework. July 23 agenda: BPC-157 (ulcerative colitis), KPV (wound healing), TB-500 (wound healing), MOTS-c (obesity, osteoporosis). July 24 agenda: Emideltide/DSIP (opioid withdrawal, chronic insomnia, narcolepsy), Semax (cerebral ischemia, migraine, trigeminal neuralgia), Epitalon (insomnia). Federal Register notice: FR Doc. 2026-07361, April 16 2026.

BPC-157 legal status 2026 →

FDA staff recommendation: AGAINST all seven

FDA staff's June 29–30, 2026 briefing to PCAC recommended against adding any of the seven peptides to the 503A Bulks List. The staff analysis applied the three-part 503A test: (1) whether the substance appears in a USP monograph — none of the seven do; (2) whether the substance is a component of an FDA-approved drug — none meet this criterion; (3) whether there is a clinical need that would be inadequately met by an approved commercial drug available in appropriate strength, dosage form, or delivery system. FDA staff concluded that insufficient clinical evidence exists for the nominated indications to satisfy the clinical need standard. For BPC-157, the pivotal data FDA cited was primarily animal studies with a small number of early-phase human pilots. For Semax, the primary evidence is Russian clinical data from the 1990s-2000s. For TB-500, the evidence base is the parent full-length Thymosin β4 (RegeneRx ophthalmic Phase 2/3), not the TB-500 fragment specifically. The PCAC vote is non-binding; FDA makes the final determination through formal rulemaking.

BPC-157 regulatory context →

What this vote does NOT mean for RUO research supply

The PCAC July 2026 vote is specifically about the 503A compounding framework — it governs whether licensed compounding pharmacies can prepare these substances for individual patients under prescriptions. It does NOT govern the research-use-only (RUO) market. Research-use-only supply is a separate legal category: RUO compounds are sold for in-vitro and pre-clinical laboratory research, not as medications for humans, and are governed by different regulatory frameworks than the compounding pharmacy sector. Titan Peptide Lab is an RUO research supplier, not a 503A compounding pharmacy. An unfavorable PCAC vote — including the FDA staff recommendation against the seven compounds — does not alter Titan's legal ability to supply BPC-157, TB-500, Semax, DSIP, or other RUO research compounds for laboratory research purposes. The two channels (compounding pharmacy vs RUO research) operate under different legal frameworks.

TB-500 legal status 2026 →

The seven compounds: evidence context and Titan supply status

BPC-157: 15-mer, body protection compound, original isolation from human gastric juice (Sikiric 1993). Animal data: wound healing, colitis, tendon repair. Human: small pilots. Titan in stock (vial $54.99 + nasal $64.99). TB-500: 7-mer LKKTETQ, fragment of Thymosin β4. Studied for wound healing via G-actin sequestration/ILK. Human safety data is from full Tβ4, not the fragment. Titan in stock ($89.99 vial). KPV: 3-mer Lys-Pro-Val, α-MSH C-terminal fragment. NF-κB suppression in gut epithelial cells. No human trial. NOT stocked by Titan. MOTS-c: 16-mer mitochondrial-derived peptide (12S rRNA). Metabolic/longevity models. NOT stocked. DSIP/Emideltide: nonapeptide WAGGDASGE. Sleep and opioid withdrawal animal models; contradictory human insomnia data. Titan in stock (DSIP nasal $62.99). Semax: heptapeptide ACTH(4-10) analog. Russian studies (stroke, cognition). MC4R agonism, BDNF/NGF. Titan in stock (nasal $59.99). Epitalon: AEDG tetrapeptide. Telomerase/anti-aging animal models. No human trial data for Titan to cite. NOT stocked.

Semax legal status 2026 →

What happens after the PCAC vote

The PCAC's recommendation is advisory. After the vote, FDA reviews the committee's recommendation and public comments from the docket (public comment period closed July 22, 2026). FDA then makes its own determination and publishes a Federal Register notice with its proposed rule. For any substance FDA proposes to EXCLUDE from the 503A list, there is a public comment period on the proposed exclusion. Only after a final rule is published does the regulatory status of the compounding pathway change. This process typically takes 12–24+ months after the PCAC vote. For substances already absent from the 503A list (which these seven are), an unfavorable PCAC recommendation and subsequent FDA exclusion would formalize what is already the practical state — compounding pharmacies currently cannot legally use these substances under 503A anyway. The RUO research supply channel is unaffected by this process.

DSIP legal status 2026 →

Freshness law: update this page after the actual PCAC votes

This page reflects pre-meeting information as of July 22, 2026. The actual PCAC votes and committee discussion from July 23–24 will be the authoritative record. Key things to track after the meeting: (1) Did PCAC vote to recommend or not recommend each compound? (Non-binding, but signals FDA direction.) (2) Were any compound-specific nuances raised in committee discussion? (3) What is the expected FDA rulemaking timeline? (4) Did any compound receive a split vote or conditional recommendation? Titan will update the individual compound legal-status pages (bpc-157-legal-status-2026, tb-500-legal-status-2026, semax-legal-status-2026, dsip-legal-status-2026) with the actual outcomes once the official FDA record is published. The PCAC meeting webcast is available via FDA's public meeting registration.

Semax legal status 2026 →

The detail, in plain terms

PCAC July 2026 — seven-compound agenda reference.

The PCAC vote is advisory and governs 503A compounding pharmacies only — not the RUO research market. FDA staff recommended against all seven. Formal rulemaking required before any status change.

July 23 — BPC-157: Body protection compound; UC indication; animal-dominant evidence base; FDA staff: against. Titan stocks vial $54.99 + nasal $64.99.
July 23 — KPV: Lys-Pro-Val tripeptide α-MSH fragment; wound healing; cell/animal data only; FDA staff: against. Titan: NOT stocked.
July 23 — TB-500: LKKTETQ Thymosin β4 fragment; wound healing; human evidence from parent Tβ4 (RegeneRx); FDA staff: against. Titan stocks vial $89.99.
July 23 — MOTS-c: 16-mer mitochondrial peptide; obesity/osteoporosis; animal models; FDA staff: against. Titan: NOT stocked.
July 24 — DSIP/Emideltide: Nonapeptide sleep peptide; insomnia/opioid withdrawal; contradictory human data; FDA staff: against. Titan stocks DSIP nasal $62.99.
July 24 — Semax: ACTH(4-10) heptapeptide analog; cerebral ischemia/migraine; Russian studies only; FDA staff: against. Titan stocks nasal $59.99.
July 24 — Epitalon: AEDG tetrapeptide; insomnia; animal telomerase data; FDA staff: against. Titan: NOT stocked.
PCAC vote status: Non-binding recommendation only. FDA formal rulemaking required before any 503A change. Typical timeline: 12–24+ months post-meeting.
RUO supply impact: None directly. 503A governs compounding pharmacies, not the RUO research supply channel. Titan's BPC-157, TB-500, Semax, DSIP remain available as RUO compounds.

Questions researchers ask

Before you order.

What did the PCAC vote on in July 2026?: The FDA Pharmacy Compounding Advisory Committee (PCAC) met July 23–24, 2026 to vote on whether seven peptide bulk drug substances — BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon — should be recommended for inclusion on the Section 503A Bulk Drug Substances List. The 503A Bulks List governs which substances licensed compounding pharmacies may use to compound preparations for individual patients. FDA staff's pre-meeting recommendation was against adding all seven. The PCAC vote is advisory and non-binding; FDA must complete formal rulemaking before any regulatory change takes effect.
Does the PCAC vote affect Titan's ability to sell BPC-157, TB-500, or Semax?: No. The PCAC review is about the 503A compounding pharmacy framework — whether licensed pharmacies can compound these substances for patients under prescriptions. Titan Peptide Lab is a research-use-only (RUO) supplier, not a 503A compounding pharmacy. The RUO and compounding pharmacy channels operate under different legal frameworks. An unfavorable PCAC recommendation — or even a subsequent FDA rule excluding these compounds from the 503A list — does not affect the legality of Titan supplying BPC-157, TB-500, Semax, or DSIP as RUO research compounds for in-vitro laboratory use.
If PCAC votes against BPC-157, is it now illegal to buy or sell?: No. A negative PCAC recommendation means the committee is advising FDA not to add BPC-157 to the 503A Bulks List for compounding pharmacies. It does not ban the compound, change its status as a research chemical, or make it illegal to purchase as an RUO research compound. BPC-157 is currently not on the 503A Bulks List anyway — compounding pharmacies already cannot legally use it under 503A. The PCAC vote and any subsequent FDA rulemaking would formalize that existing status, not create a new restriction. For researchers purchasing it as an RUO compound for in-vitro laboratory research, the legal basis is different from the compounding framework.
Why did FDA staff recommend against all seven peptides?: FDA staff applied the three-part 503A test: USP monograph (none qualify); FDA-approved drug component (none qualify); clinical need not adequately met by approved drugs. For the clinical need criterion, FDA staff concluded that the evidence base for each nominated indication is insufficient — primarily animal studies with limited, early-phase, or non-replicated human data. For BPC-157, the evidence is overwhelmingly animal-model data with only small human pilots. For Semax, the primary evidence is Russian clinical studies that haven't been replicated in Western trials. For TB-500, human safety data exists for the parent Thymosin β4 (RGN-259 ophthalmic Phase 2/3) but not specifically for the TB-500 fragment.
When will the PCAC vote result be official?: The PCAC committee discussion and vote occurred July 23–24, 2026. The vote transcript and meeting records are published by FDA as part of the public record, typically within weeks to months after the meeting. However, the PCAC vote is advisory — the regulatory outcome depends on FDA's formal rulemaking response, which typically takes 12–24 months or more after the advisory committee meeting. Titan will update the individual compound legal-status pages (BPC-157, TB-500, Semax, DSIP) with confirmed outcomes once the official FDA record is published.